For the Inventor, By the Inventor

Enter assignee name

Zambon S.p.a.

USPTO Granted Patents = 79

% Expired Patents = 3.8

CIPO Patents = 3

EPO Patents = 22

Trademarks = 19

Forward Citations = 480

Loading Chart...

Loading Chart...

84 inventors (with patents filed for the assignee):

Claudio Giordano (27 out of 59 patents)

Graziano Castaldi (23 out of 69 patents)

Dario Chiarino (21 out of 33 patents)

4. Davide Della Bella (18 out of 22 patents)

5. Angelo Carenzi (14 out of 24 patents)

6. Silvia Cavicchioli (10 out of 14 patents)

7. Fulvio Uggeri (9 out of 59 patents)

8. Giancarlo Jommi (7 out of 7 patents)

9. Alberto Moretto (4 out of 4 patents)

10. Giovanni Caponetti (4 out of 26 patents)

11. Loretta Maggi (4 out of 6 patents)

12. Mauro Napoletano (4 out of 30 patents)

13. Franco Pellacini (4 out of 31 patents)

14. Roberto Pagliarin (4 out of 4 patents)

15. Mariano Meneghin (4 out of 7 patents)

Core Competencies:

N-acetylcysteine

Antibiotic Activity

Analgesic Compounds

Pharmaceutical Formulations

Bacterial Infections

Vaginal Dryness

Optically Active Compounds

Thiazolidine Derivatives

Gabapentin

Ischemia Treatment

Myotonia Treatment

Stereoselective Processes

79 patents: Sort by Forward Citations

1. 12178841 - Treatment of non-cystic fibrosis bronchiectasis (2024-12-31),

2. 12102660 - Association of N-acetylcysteine and colistin for use in bacterial infections (2024-10-01),

3. 11918552 - N-acetylcysteine for use as antibacterial agent (2024-03-05),

4. 11707441 - Safinamide for treating myotonia (2023-07-25),

5. 11382948 - Association of N-acetylcysteine and colistin for use in bacterial infections (2022-07-12),

6. 11103457 - Pharmaceutical compositions comprising safinamide (2021-08-31),

7. 10792257 - Pharmaceutical compositions comprising safinamide (2020-10-06),

8. 10583082 - Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation (2020-03-10),

9. 10517828 - Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation (2019-12-31),

10. 10449147 - Pharmaceutical composition containing budesonide and formoterol (2019-10-22),

11. 10226421 - Pharmaceutical composition containing budesonide and formoterol (2019-03-12),

12. 9808427 - Swallowable N-acetylcysteine tablets (2017-11-07),

13. 9248151 - Multipurpose gel for vaginal dryness with direct and delayed effect (2016-02-02),

14. 8927017 - Pharmaceutical preparation containing gabapentin (2015-01-06),

15. 8522774 - Aerosol apparatus, in particular for children (2013-09-03),

Company Overview

Zambon S.p.a., headquartered in Vicenza, Italy, specializes in the development and manufacturing of pharmaceutical compositions. The company focuses on innovative solutions in various therapeutic areas, including respiratory diseases, bacterial infections, and pain management. Key technology topics include N-acetylcysteine, antibiotic activity, and analgesic compounds, alongside advancements in pharmaceutical formulations. Zambon is committed to addressing medical needs through research and development of effective treatments, particularly in the realm of optically active compounds and thiazolidine derivatives.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

79 Patents

#3 in Vicenza

#120 in Italy

#9,571 in the World

Zambon S.p.a.

Forward Citations = 480

84 inventors:

Claudio Giordano (27 out of 59 patents)

Graziano Castaldi (23 out of 69 patents)

Dario Chiarino (21 out of 33 patents)

4. Davide Della Bella (18 out of 22 patents)

5. Angelo Carenzi (14 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zambon S.p.a.. Retrieved from https://idiyas.com/company/zambon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…